The CAR T-immunotherapy tisagenlecleucel (Kymriah®) has approved for patients with follicular lymphoma (FL) whose cancer has returned or worsened despite at least two earlier treatments. FL is the most common slow growing form of non-Hodgkin’s lymphoma, which becomes more aggressive with each relapse—making it essential to continue research into new treatment options.
No comments:
Post a Comment